Edition:
United States

NxStage Medical Inc (NXTM.OQ)

NXTM.OQ on NASDAQ Stock Exchange Global Select Market

27.51USD
20 Oct 2017
Change (% chg)

-- (--)
Prev Close
$27.51
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
275,866
52-wk High
$30.80
52-wk Low
$20.47

Chart for

About

NxStage Medical, Inc. is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate... (more)

Overall

Beta: -0.06
Market Cap(Mil.): $1,815.86
Shares Outstanding(Mil.): 66.01
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 163.65 16.52
EPS (TTM): -- -- --
ROI: -- 9.60 11.32
ROE: -- 14.98 15.18

BRIEF-NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage system one

* NxStage Medical announces FDA clearance for solo home hemodialysis using NxStage® system one™

Aug 28 2017

BRIEF-Nxstage Medical Inc says subsidiary is partnering with Dialyze Direct​

* ‍Nxstage kidney care subsidiary is partnering with Dialyze Direct​ Source text for Eikon: Further company coverage:

Aug 11 2017

Fresenius Medical banks on home dialysis with $2 billion NxStage acquisition

FRANKFURT Germany's Fresenius Medical Care (FMC) has struck a $2 billion deal to acquire U.S. home dialysis equipment maker NxStage Medical Inc , looking to capitalize on a trend for more patients to opt for domestic treatment.

Aug 07 2017

UPDATE 3-Fresenius Medical banks on home dialysis with $2 bln NxStage acquisition

* FMC shares down more than 2pct, biggest DAX losers (Rewrites first paragraph, adds background on shift to home dialysis and FMC's previous acquisitions, CEO quote)

Aug 07 2017

BRIEF-NxStage Medical posts Q2 loss of $0.03 per share

* NxStage Medical - in light of acquisition agreement between Fresenius Medical Care and NxStage, NxStage is no longer providing financial guidance

Aug 07 2017

BRIEF-Nxstage Medical announces FDA clearance for new system one hemodialysis system

* Nxstage Medical announces fda clearance for its new system one hemodialysis system

May 10 2017

BRIEF-NxStage Q1 revenue $96.8 million

* NxStage Medical Inc - revising annual home revenue growth target to be between 10 to 13 pct for 2017 versus previous 15 pct target

May 09 2017

Competitors

Earnings vs. Estimates